Ascendis Pharma A/S
ASND
Rangering i aksjer
#1497
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing... Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.
Aksjekurs
$234.15
Markedsverdi
$14.61B
Endring (1 dag)
1.82%
Endring (1 år)
14.10%
Land
DK
Handel Ascendis Pharma A/S (ASND)
Kategori
Healthcare
Historikk for aksjesplitt for Ascendis Pharma A/S (ASND)
Aksjen Ascendis Pharma A/S (symbol: ASND) har gjennomgått totalt 0 aksjesplitt.
Den nyeste splittelsen skjedde Oct 20, 2026.
Én ASND-aksje kjøpt før Oct 20, 2026 tilsvarer i dag 0 ASND-aksjer.
Den nyeste splittelsen skjedde Oct 20, 2026.
Én ASND-aksje kjøpt før Oct 20, 2026 tilsvarer i dag 0 ASND-aksjer.
Liste over aksjesplitt
| År | Splitt | Multiplikator | Kumulativ multiplikator |
|---|---|---|---|
| Ikke nok data for de angitte datoene. | |||
Aksjesplitt for lignende selskaper eller konkurrenter
| Selskap | Antall aksjesplitt | Kumulativ multiplikator | Land |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
